Sofiva Genomics Co.,Ltd.

Informe acción TPEX:6615

Capitalización de mercado: NT$984.7m

Sofiva GenomicsLtd Resultados de beneficios anteriores

Pasado controles de criterios 1/6

Sofiva GenomicsLtd's earnings have been declining at an average annual rate of -15.7%, while the Healthcare industry saw earnings growing at 6.8% annually. Revenues have been declining at an average rate of 1.1% per year. Sofiva GenomicsLtd's return on equity is 4%, and it has net margins of 5.2%.

Información clave

-15.7%

Tasa de crecimiento de los beneficios

-15.9%

Tasa de crecimiento del BPA

Crecimiento de la industria Healthcare 9.1%
Tasa de crecimiento de los ingresos-1.1%
Rentabilidad financiera4.0%
Margen neto5.2%
Última actualización de beneficios30 Jun 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Some Investors May Be Worried About Sofiva GenomicsLtd's (GTSM:6615) Returns On Capital

Apr 14
Some Investors May Be Worried About Sofiva GenomicsLtd's (GTSM:6615) Returns On Capital

Estimating The Fair Value Of Sofiva Genomics Co.,Ltd. (GTSM:6615)

Mar 18
Estimating The Fair Value Of Sofiva Genomics Co.,Ltd. (GTSM:6615)

Sofiva Genomics Co.,Ltd. (GTSM:6615) Investors Should Think About This Before Buying It For Its Dividend

Feb 24
Sofiva Genomics Co.,Ltd. (GTSM:6615) Investors Should Think About This Before Buying It For Its Dividend

Should Weakness in Sofiva Genomics Co.,Ltd.'s (GTSM:6615) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Jan 27
Should Weakness in Sofiva Genomics Co.,Ltd.'s (GTSM:6615) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Our Take On The Returns On Capital At Sofiva GenomicsLtd (GTSM:6615)

Jan 07
Our Take On The Returns On Capital At Sofiva GenomicsLtd (GTSM:6615)

A Look At The Intrinsic Value Of Sofiva Genomics Co.,Ltd. (GTSM:6615)

Dec 15
A Look At The Intrinsic Value Of Sofiva Genomics Co.,Ltd. (GTSM:6615)

Read This Before Buying Sofiva Genomics Co.,Ltd. (GTSM:6615) For Its Dividend

Nov 24
Read This Before Buying Sofiva Genomics Co.,Ltd. (GTSM:6615) For Its Dividend

Desglose de ingresos y gastos

Cómo gana y gasta dinero Sofiva GenomicsLtd. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).


Historial de beneficios e ingresos

TPEX:6615 Ingresos, gastos y beneficios (TWD Millions)
FechaIngresosBeneficiosGastos G+AGastos de I+D
30 Jun 24478251328
31 Mar 24475201349
31 Dec 234671213610
30 Sep 234723413512
30 Jun 234733113413
31 Mar 234833313511
31 Dec 224964313510
30 Sep 22501371358
30 Jun 22506491357
31 Mar 22510621328
31 Dec 215085713111
30 Sep 215075313012
30 Jun 215054412613
31 Mar 214943312512
31 Dec 204893512210
30 Sep 20489371218
30 Jun 20497481237
31 Mar 20506591238
31 Dec 19509631238
30 Sep 19504611198
30 Jun 19486511129
31 Mar 19469491079
31 Dec 18459471019
30 Sep 18451461008
30 Jun 18446481016
31 Mar 1843845976
31 Dec 1742445954
30 Sep 1741048914
30 Jun 1739849876
31 Mar 1738845846
31 Dec 1638443837
30 Jun 1637333809
31 Mar 1635625798
31 Dec 1534416788
31 Dec 1429523660
31 Dec 13154-23400

Ingresos de calidad: 6615 has high quality earnings.

Margen de beneficios creciente: 6615's current net profit margins (5.2%) are lower than last year (6.6%).


Análisis del flujo de caja libre vs. Beneficios


Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: 6615's earnings have declined by 15.7% per year over the past 5 years.

Acelerando crecimiento: 6615's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Beneficios vs. Industria: 6615 had negative earnings growth (-19%) over the past year, making it difficult to compare to the Healthcare industry average (3.6%).


Rentabilidad financiera

Alta ROE: 6615's Return on Equity (4%) is considered low.


Rentabilidad económica


Rendimiento del capital invertido


Descubre empresas con buenos resultados en el pasado